CSTL Castle Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CSTL matters now
Castle Biosciences, Inc. (CSTL) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.72 with -3.42% on the session and $719.4M in market capitalization; recent performance reads 1-month +10.00% and YTD -45.71%.
The latest financial table shown here is Q1 2026, with revenue of $83.7M, net income of $-14.5M, and EPS of $-0.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.7%.
The latest indexable market news headline is "Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $43.50; recent insider activity includes Oelschlager Kristen M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.37
P/S
1.88
EV/EBITDA
-845.46
DCF Value
$-196.21
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
-9.8%
Net Margin
-3.8%
ROE
-2.8%
ROA
-2.3%
ROIC
-4.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $83.7M | $-14.5M | $-0.49 |
| Q4 2025 | $87.0M | $-2.3M | $-0.08 |
| FY 2025 | $344.2M | $-24.2M | $-0.83 |
| Q3 2025 | $83.0M | $-501.0K | $-0.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.50
Target (Median)
$43.50
Target Range
$35.00 - $52.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.02
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.